385 related articles for article (PubMed ID: 9519874)
1. A transgenic mouse model for mammary carcinogenesis.
Li B; Murphy KL; Laucirica R; Kittrell F; Medina D; Rosen JM
Oncogene; 1998 Feb; 16(8):997-1007. PubMed ID: 9519874
[TBL] [Abstract][Full Text] [Related]
2. Bcl-2 expression delays mammary tumor development in dimethylbenz(a)anthracene-treated transgenic mice.
Murphy KL; Kittrell FS; Gay JP; Jäger R; Medina D; Rosen JM
Oncogene; 1999 Nov; 18(47):6597-604. PubMed ID: 10597264
[TBL] [Abstract][Full Text] [Related]
3. Transgenic mice overexpressing a dominant-negative mutant type II transforming growth factor beta receptor show enhanced tumorigenesis in the mammary gland and lung in response to the carcinogen 7,12-dimethylbenz-[a]-anthracene.
Böttinger EP; Jakubczak JL; Haines DC; Bagnall K; Wakefield LM
Cancer Res; 1997 Dec; 57(24):5564-70. PubMed ID: 9407968
[TBL] [Abstract][Full Text] [Related]
4. SV40 T/t-antigen induces premature mammary gland involution by apoptosis and selects for p53 missense mutation in mammary tumors.
Tzeng YJ; Zimmermann C; Guhl E; Berg B; Avantaggiati ML; Graessmann A
Oncogene; 1998 Apr; 16(16):2103-14. PubMed ID: 9572491
[TBL] [Abstract][Full Text] [Related]
5. Myc/p53 interactions in transgenic mouse mammary development, tumorigenesis and chromosomal instability.
McCormack SJ; Weaver Z; Deming S; Natarajan G; Torri J; Johnson MD; Liyanage M; Ried T; Dickson RB
Oncogene; 1998 May; 16(21):2755-66. PubMed ID: 9652742
[TBL] [Abstract][Full Text] [Related]
6. Cooperating oncogenic events in murine mammary tumorigenesis: assessment of ErbB2, mutant p53, and mouse mammary tumor virus.
Zelazny E; Li B; Anagnostopoulos AM; Coleman A; Perkins AS
Exp Mol Pathol; 2001 Jun; 70(3):183-93. PubMed ID: 11417997
[TBL] [Abstract][Full Text] [Related]
7. Expression of a truncated Int3 gene in developing secretory mammary epithelium specifically retards lobular differentiation resulting in tumorigenesis.
Gallahan D; Jhappan C; Robinson G; Hennighausen L; Sharp R; Kordon E; Callahan R; Merlino G; Smith GH
Cancer Res; 1996 Apr; 56(8):1775-85. PubMed ID: 8620493
[TBL] [Abstract][Full Text] [Related]
8. An overexpressed N-ras proto-oncogene cooperates with N-methylnitrosourea in mouse mammary carcinogenesis.
Mangues R; Kahn JM; Seidman I; Pellicer A
Cancer Res; 1994 Dec; 54(24):6395-401. PubMed ID: 7987834
[TBL] [Abstract][Full Text] [Related]
9. Overexpression of the colony-stimulating factor (CSF-1) and/or its receptor c-fms in mammary glands of transgenic mice results in hyperplasia and tumor formation.
Kirma N; Luthra R; Jones J; Liu YG; Nair HB; Mandava U; Tekmal RR
Cancer Res; 2004 Jun; 64(12):4162-70. PubMed ID: 15205327
[TBL] [Abstract][Full Text] [Related]
10. Hormonal and dietary modulation of mammary carcinogenesis in mouse mammary tumor virus-c-erbB-2 transgenic mice.
Yang X; Edgerton SM; Kosanke SD; Mason TL; Alvarez KM; Liu N; Chatterton RT; Liu B; Wang Q; Kim A; Murthy S; Thor AD
Cancer Res; 2003 May; 63(10):2425-33. PubMed ID: 12750262
[TBL] [Abstract][Full Text] [Related]
11. Reduced circulating insulin-like growth factor I levels delay the onset of chemically and genetically induced mammary tumors.
Wu Y; Cui K; Miyoshi K; Hennighausen L; Green JE; Setser J; LeRoith D; Yakar S
Cancer Res; 2003 Aug; 63(15):4384-8. PubMed ID: 12907608
[TBL] [Abstract][Full Text] [Related]
12. WAP-TAg transgenic mice and the study of dysregulated cell survival, proliferation, and mutation during breast carcinogenesis.
Li M; Lewis B; Capuco AV; Laucirica R; Furth PA
Oncogene; 2000 Feb; 19(8):1010-9. PubMed ID: 10713684
[TBL] [Abstract][Full Text] [Related]
13. Cooperative interaction between mutant p53 and des(1-3)IGF-I accelerates mammary tumorigenesis.
Hadsell DL; Murphy KL; Bonnette SG; Reece N; Laucirica R; Rosen JM
Oncogene; 2000 Feb; 19(7):889-98. PubMed ID: 10702797
[TBL] [Abstract][Full Text] [Related]
14. Expression of a p53 mutant in the epidermis of transgenic mice accelerates chemical carcinogenesis.
Wang XJ; Greenhalgh DA; Jiang A; He D; Zhong L; Medina D; Brinkley BR; Roop DR
Oncogene; 1998 Jul; 17(1):35-45. PubMed ID: 9671312
[TBL] [Abstract][Full Text] [Related]
15. Mammary carcinogenesis in transgenic mice expressing a dominant-negative mutant of DNA polymerase beta in their mammary glands.
Wang L; Bhattacharyya N; Rabi T; Wang L; Banerjee S
Carcinogenesis; 2007 Jun; 28(6):1356-63. PubMed ID: 17166880
[TBL] [Abstract][Full Text] [Related]
16. Decreased tumor formation in 7,12-dimethylbenzanthracene-treated stromelysin-1 transgenic mice is associated with alterations in mammary epithelial cell apoptosis.
Witty JP; Lempka T; Coffey RJ; Matrisian LM
Cancer Res; 1995 Apr; 55(7):1401-6. PubMed ID: 7882342
[TBL] [Abstract][Full Text] [Related]
17. Somatic mutation of p53 leads to estrogen receptor alpha-positive and -negative mouse mammary tumors with high frequency of metastasis.
Lin SC; Lee KF; Nikitin AY; Hilsenbeck SG; Cardiff RD; Li A; Kang KW; Frank SA; Lee WH; Lee EY
Cancer Res; 2004 May; 64(10):3525-32. PubMed ID: 15150107
[TBL] [Abstract][Full Text] [Related]
18. A mammary-specific model demonstrates the role of the p53 tumor suppressor gene in tumor development.
Jerry DJ; Kittrell FS; Kuperwasser C; Laucirica R; Dickinson ES; Bonilla PJ; Butel JS; Medina D
Oncogene; 2000 Feb; 19(8):1052-8. PubMed ID: 10713689
[TBL] [Abstract][Full Text] [Related]
19. Targeted production of proprotein convertase PC1 enhances mammary development and tumorigenesis in transgenic mice.
Blanchard A; Iwasiow B; Yarmill A; Fresnosa A; Silha J; Myal Y; Murphy LC; Chrétien M; Seidah N; Shiu RP
Can J Physiol Pharmacol; 2009 Oct; 87(10):831-8. PubMed ID: 20052009
[TBL] [Abstract][Full Text] [Related]
20. p130Cas as a new regulator of mammary epithelial cell proliferation, survival, and HER2-neu oncogene-dependent breast tumorigenesis.
Cabodi S; Tinnirello A; Di Stefano P; Bisarò B; Ambrosino E; Castellano I; Sapino A; Arisio R; Cavallo F; Forni G; Glukhova M; Silengo L; Altruda F; Turco E; Tarone G; Defilippi P
Cancer Res; 2006 May; 66(9):4672-80. PubMed ID: 16651418
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
